The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization - 28/05/22
, Feng Ye a, ⁎ Highlights |
• | RFA can not only be regarded as a curative therapy for tumors within Milan criteria, but also has been investigated in HCC patients within up-to-seven criteria in several studies. Using TACE as downstaging therapy to make subsequent RFA procedure applicable in HCC patients with a tumor burden outside the up-to-seven criteria initially is worthy of exploring. |
• | This was the first study to investigate the efficacy of RFA after downstaging by using TACE for HCC patients with BCLC B1 stage. |
• | We evaluated two groups of patients with HCC- downstaging TACE+RFA, RFA group in a propensity-matched analysis. It was demonstrated that RFA after downstaging into BCLC B1 stage using TACE offered a safe and effective treatment regime for patients with HCC beyond the up-to-seven criteria. The OS and RFS of patients who received RFA for downstaged HCC with TACE was comparable to those patients with HCC who initially in BCLC B1 stage. |
Abstract |
Purpose |
To evaluate the effectiveness of radiofrequency ablation (RFA) as a curative therapy for BCLC B1 stage (beyond Milan criteria but within up-to-seven criteria) hepatocellular carcinoma (HCC) followed by downstageing by using transarterial chemoembolization (TACE).
Methods |
We retrospectively recruited patients underwent RFA alone and who underwent RFA following downstaging into BCLC B1 stage using TACE between April 2011 and August 2017. Overall survival (OS) and recurrence-free survival (RFS) were compared using the Kaplan-Meier method. A propensity score analysis was performed to reduce potential bias.
Results |
The downstaging TACE+RFA and RFA alone group comprised 50 and 110 patients, respectively. After propensity score matching, the 1-, 2-, and 3-year OS rates were 100%, 92%, 74%, respectively, the 1-, 2-, and 3-year RFS rates were 40%, 36%, and 20%, respectively, for patients in the downstaging TACE+RFA group. The 1-, 2-, and 3-year OS rates were 96%, 90%, and 82%, respectively, the 1-, 2-, and 3-year RFS rates were 51%, 32%, and 32%, respectively, for patients in the RFA group. No statistical differences were observed between the two groups in terms of OS and RFS before and after matching.
Conclusion |
RFA after downstaging into BCLC B1 stage using TACE offered a safe and effective treatment regime for patients with HCC beyond the up-to-seven criteria. The intermediate-term OS and RFS of RFA following downstaging into BCLC B1 stage using TACE for HCC were similar to that of patients who were initially in BCLC B1stage.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Radiofrequency ablation, Hepatocellular carcinoma, Transarterial chemoembolization, Downstaging
Mappa
Vol 46 - N° 4
Articolo 101878- Aprile 2022 Ritorno al numero
Articolo precedente
- An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma
- Xinyun Zhang, Mengmeng Jiang, Xihao Zhang, Jinliang Zhang, Hongxing Guo, Chenxuan Wu
- Infectious complications of portal biliopathy leading to liver transplantation
- Thomas Levi-Strauss, Geoffroy Vanbiervliet, Patrick Chevallier, Rodolphe Anty, Albert Tran, Dann Joseph Ouizeman
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?